Phase 3 ABBV-1480 PD-1×VEGF bispecific antibody vs pembrolizumab in 1L sqNSCLC
Trial status
Currently Recruiting
Status as of
Got an update?- Trial ID
- NCT07756645 on ClinicalTrials.gov
- Cancer type
- Non-Small Cell Lung Cancer (NSCLC)
- Stage of research
- Registrational
- Location
- Fort Wayne, IN and Rio Piedras, PR (US, multi-center)
- Published in
- New in Oncology - Nov 19, 2026
AbbVie’s Phase 3, randomized, multiregional, open-label study tests whether ABBV-1480 plus platinum-doublet chemotherapy improves outcomes versus pembrolizumab (Merck’s PD-1 monoclonal antibody) plus the same chemotherapy in previously untreated, unresectable stage IIIB/IIIC or metastatic stage IV squamous NSCLC. ABBV-1480 (also known as RC148, licensed by AbbVie from RemeGen outside Greater China) is a PD-1/VEGF-directed bispecific designed to simultaneously release PD-1–mediated T-cell inhibition and block VEGF-driven angiogenesis and immune suppression in the tumor microenvironment. Participants receive IV ABBV-1480 + carboplatin (DNA crosslinking platinum) with paclitaxel or nab-paclitaxel (microtubule inhibitors), or IV pembrolizumab + the same chemo backbone. The key commercial/scientific angle is whether a single-molecule PD-1 + VEGF approach can outperform PD-1 + chemo without adding a separate anti-VEGF drug, in a setting where today’s care is pembrolizumab + carboplatin/taxane (or other PD-1/PD-L1 regimens) for eligible patients, with later-line options including docetaxel ± anti-angiogenic therapy and antibody-drug conjugates in selected contexts.
More in non-small cell lung cancer
-
New trial · Nov 19, 2026 · NCT07393555
Phase 2 sacituzumab govitecan (TROP2 ADC) ± ivonescimab (PD-1×VEGF bispecific) in AGA+ NSCLC -
New trial · Nov 19, 2026 · NCT07899801
Phase 1a/1b zanidatamab (HER2 bispecific antibody) + zongertinib (HER2 TKI) in HER2-mutated NSCLC -
New trial · Nov 12, 2026 · NCT07874490
Phase 2 osimertinib EGFR inhibitor plus cyclosporine A calcineurin/NFAT inhibitor in EGFR-mutant NSCLC -
New trial · Nov 12, 2026 · NCT07871214
Phase 2 pumitamig PD‑L1×VEGF‑A bispecific antibody neoadjuvant platform in resectable NSCLC. -
New trial · Nov 12, 2026 · NCT07864584
Phase 1/2 NHT102 inhaled azacitidine DNA hypomethylating agent (DNMT inhibitor) in NSCLC
